Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 , a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025
